Skip to search formSkip to main contentSkip to account menu

BMS-275291

Known as: D2163, N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide, REBIMASTAT 
A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits… 
National Institutes of Health

Related topics

Related topics

9 relations
Angiogenesis InhibitionExtracellular Matrix DegradationMMP1 protein, humanMMP14 protein, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Venous thromboembolism and nonsmall cell lung cancer
Advanced nonsmall cell lung cancer (NSCLC) is associated with venous thromboembolism (VTE). However, to the authors' knowledge… 
Highly Cited
2006
Highly Cited
2006
A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
Background: BMS-275291 is a selective matrix metalloproteinase inhibitor (MMPI) that does not inhibit sheddases implicated in the… 
Highly Cited
2005
Highly Cited
2005
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada…
PURPOSE To determine whether BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor (MMPI), added to systemic… 
Highly Cited
2004
Highly Cited
2004
A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer
Purpose: BMS-275291 is a novel broad-spectrum inhibitor of matrix metalloproteinase (MMPs) rationally designed to spare a class… 
Highly Cited
2003
Highly Cited
2003
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.
PURPOSE The purpose of this study was to evaluate the feasibility of incorporating a novel wound angiogenesis assay into a Phase… 
Review
2003
Review
2003
Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix…
The MMPs2 are a family of zinc-containing endopeptidases that degrade various components of the ECM. A number of MMPs have been… 
Review
2002
Review
2002
BMS-275291. Bristol-Myers Squibb.
Bristol-Myers Squibb (BMS) is developing BMS-275291, which is a matrix metalloproteinase (MMP) inhibitor, for the potential… 
Highly Cited
2001
Highly Cited
2001
Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.
BMS-275291 is an p.o. bioavailable, sulfhydryl-based matrix metalloproteinase (MMP) inhibitor currently in clinical development… 
Review
2001
Review
2001
Angiogenesis inhibitors in the treatment of lung cancer.
Review
2001
Review
2001
Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)